Pharmacological Characterization of Abediterol, a Novel Inhaled β2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical Models-Reference-Cited by-同舟云学术

Pharmacological Characterization of Abediterol, a Novel Inhaled β2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical Models

Published:2012-05-15 Issue:2 Volume:342 Page:497-509
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Aparici Mònica,Gómez-Angelats Mireia,Vilella Dolors,Otal Raquel,Carcasona Carla,Viñals Marisa,Ramos Israel,Gavaldà Amadeu,De Alba Jorge,Gras Jordi,Cortijo Julio,Morcillo Esteban,Puig Carlos,Ryder Hamish,Beleta Jorge,Miralpeix Montserrat

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference40 articles.

1. Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo;Ball;Br J Pharmacol,1991

2. In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action

3. The short, the long and the “ultra-long”: Why duration of bronchodilator action matters in chronic obstructive pulmonary disease

4. Efficacy and safety of single doses of inhaled LAS100977 in patients with persistent asthma [abstract];Beier;Am J Respir Crit Care Med,2010

5. Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anwendung von Organometallkatalysatoren in der API-Synthese;Organometallik in der Prozesschemie;2024

2. Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays;Handbook of Experimental Pharmacology;2024

3. Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update;Expert Opinion on Pharmacotherapy;2023-11-15

4. Asthma and COPD: A Focus on β-Agonists – Past, Present and Future;Handbook of Experimental Pharmacology;2023

5. New drugs under development for COPD;Minerva Medica;2022-07